Discontinuation report NORPROLAC
Report ID | 129605 |
Drug Identification Number | 02223767 |
Brand name | NORPROLAC |
Common or Proper name | Quinagolide Hydrochloride |
Company Name | FERRING INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | QUINAGOLIDE |
Strength(s) | 0.075MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 30 tablets per carton |
ATC code | G02CB |
ATC description | OTHER GYNECOLOGICALS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2020-12-02 |
Actual discontinuation date | 2020-12-09 |
Remaining supply date | 2020-12-02 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | NORPROLAC 150 mcg tablets (DIN 02223767) and NORPROLAC starter pack containing 25 mcg (DIN 02223740) and 50 mcg (DIN 02223759) tablets are in stock and available. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 200 YORKLAND BLVD TORONTO, ONTARIO CANADA M2J 5C1 |
Company contact information | 1-800-263-4057 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-12-04 | English | Compare |
v2 | 2020-12-04 | French | Compare |
v3 | 2020-12-11 | English | Compare |
v4 | 2020-12-11 | French | Compare |
Showing 1 to 4 of 4